Introduction
Transforming growth factor-b (TGF-b) is a multifunctional cytokine that regulates cell growth and differentiation, apoptosis, and the production of extracellular matrix components (reviewed in Miyazono et al., 2000; Derynck et al., 2001) . The Smad signaling pathway, which acts downstream of TGF-b, is composed of the TGF-b type I and type II receptors (TbRI and TbRII) and the Smad proteins. When the TGF-b ligand binds to TbRII, a heteromeric complex of TbRI and TbRII is formed, and TbRI is activated. The cytoplasmic Smad2 and Smad3 proteins are then phosphorylated by the activated TbRI kinase, which allows them to form a heteromeric complex with Smad4. This Smad complex is translocated into the nucleus, where it forms a complex with transcription factors and coactivators, such as the c-Jun/c-Fos complex and CBP/ p300, and then activates TGF-b-responsive gene transcription (reviewed in Miyazono et al., 2000; Derynck et al., 2001) .
The Smad signal is known to inhibit the growth of most epithelial cells. Impairment of the Smad pathway causes escape from growth inhibition and leads to the promotion of cell proliferation, thereby contributing to carcinogenesis. Several genetic or epigenetic alterations of the components of the Smad pathway have been identified in several human cancers (Markowitz et al., 1995; Hahn et al., 1996; Schutte et al., 1996; Togo et al., 1996; Miyaki et al., 1999; Wang et al., 2000) . Mutations or deletion of the Smad4 gene, which was originally designated as the tumor suppressor gene DPC4 (deleted in pancreatic carcinoma, locus 4), have been detected in 50% of all pancreatic cancers , and we reported previously that many pancreatic cancer cell lines have impaired TGF-b-Smad signaling due to a functionally inactivated Smad4 (Ijichi et al., 2001) . The growth inhibition induced by TGF-b, which is mainly G1-S cell cycle arrest, is mediated by the upregulation of cyclin-dependent kinase (CDK) inhibitors, which include p15/INK4b and p21/WAF1, and by the downregulation of c-Myc (reviewed in Miyazono et al., 2000; Derynck et al., 2001) . Most notably, it has been reported that the Smad complex directly activates the promoter region of the p21/WAF1 gene in cooperation with the ubiquitous transcription factor Sp1 (Moustakas and Kardassis, 1998; Pardali et al., 2000) , which indicates that p21/WAF1 is one of the major target genes of the TGF-b-Smad pathway.
TGF-b also promotes tumor cell invasion and metastasis (Cui et al., 1996; Oft et al., 1998) . Epithelial to mesenchymal transdifferentiation (EMT) is induced by TGF-b and is considered to play an important role in the changes that promote tumor cell invasion and metastasis (Cui et al., 1996; Oft et al., 1998; Bhowmick et al., 2001 ). In the case of EMT, it was shown that the TGF-b signal functions in a Smad-independent fashion (Bhowmick et al., 2001; Yu et al., 2002) . However, the characteristics and significance of the Smad-independent signaling pathway remain unresolved. As increased expression of TGF-b is often detected in tumors in which the TGF-b-Smad signal is frequently inactivated, including pancreatic cancers (Derynck et al., 1983; Friess et al., 1993) , it is possible that these tumors develop in a cell-autonomous manner via the TGF-bSmad-independent pathway.
In this study, we used cDNA microarray analysis to investigate the target molecules that are induced by TGF-b in the Smad4-independent system. Unexpectedly, we found p21/WAF1 induction by TGF-b in Smad4-null cells. We then examined the intermediate pathway to elucidate whether Smad2/3 is involved in transcriptional activation of the p21/WAF1 promoter region.
Results
Smad4-independent signaling may be as widespread as Smad4-dependent signaling To screen for target genes that are regulated by TGF-b, we performed cDNA microarray analysis using an inhouse cDNA chip containing 2280 named genes. Selected sample pairs (described in the Materials and methods section) were analysed by competitive hybridization on the chips (Figure 1 ), and clones that showed greater than two-fold upregulation or less than 0.5-fold downregulation were regarded as TGF-b-regulated target genes. In Group 1, 5/2280 clones were upregulated and 10/2280 clones were downregulated by TGFb. In Group 2, 4/2280 clones were upregulated and 2/ 2280 clones were downregulated. In Group 3, 6/2280 clones were upregulated and 5/2280 clones were downregulated (Table 1) . Two clones were upregulated in both Groups 1 and 3; these clones were considered to be upregulated in a Smad4-independent manner (Tables 1  and 2) .
On the other hand, only one clone was upregulated in both Groups 2 and 3, and this clone was listed as being upregulated in a Smad4-dependent manner (Tables 1  and 2 ). These three genes were analysed by quantitative RT-PCR, revealing mRNA induction of p21/WAF1 and nel-related protein, but not of ATPase (Figure 3 and data not shown). The numbers of Smad4-dependent and -independent target genes were similar, although a limited number of genes were loaded on the array.
Two downregulated clones were common to Groups 1 and 3, one of which was also common to Group 2.
To confirm the restoration of Smad4 function in the cells that were transfected with the Smad4 expression plasmid, we performed two luciferase assays using (1) p3TP-lux, which is the most frequently used reporter system for TGF-b-Smad signal transduction, and (2) E2F-luc, which contains six tandem repeats of the E2F consensus binding sequence. Cells that were transfected with the Smad4 expression plasmid showed transcriptional inducibility of p3TP-lux by TGF-b. Furthermore, the activity of E2F-luc was apparently decreased in these cells, thereby demonstrating functional Smad4 expression (Figure 2) .
Although the Smad signaling pathway is the only well-characterized system downstream of TGF-b, the results of cDNA microarray analysis suggest that the Smad4-independent pathway may be as ubiquitous as the Smad4-dependent pathway in the pancreatic cancer cell line.
The p21/WAF1 gene is upregulated by TGF-b in Smad4-null cells
The p21/WAF1 gene is one of the major target genes of the TGF-b-Smad pathway. However, our microarray analysis demonstrated that p21/WAF1 was upregulated by TGF-b in Smad4-null cells, that is, via the Smad4-independent pathway. This result prompted us to focus The following comparisons were made: Group 1, the results of the analyses with probes (b) and (a) were compared to detect clones that were regulated by TGF-b in a Smad4-independent manner; Group 2, the results of the analyses with probes (d) and (b) were compared to detect clones that were regulated by TGF-b in a Smad4-dependent manner; Group 3, the results of the analyses with probes (d) with (a) were compared to detect all clones that were induced by TGF-b, that is, both Smad4-dependent and -independent clones Smad4-independent gene regulation by TGF-b H Ijichi et al on regulation of the p21/WAF1 gene. We performed quantitative RT-PCR and Western blotting analyses on the pancreatic cancer cell line BxPC-3. Quantification of p21/WAF1 mRNA levels using RT-PCR revealed statistically significant upregulation by TGF-b 2 h after stimulation ( Figure 3a ). In addition, Western blotting showed a greater increase in p21/WAF1 protein production in the presence of TGF-b (Figure 4a ). The upregulation of p21/WAF1 mRNA and protein by TGF-b was also observed in another Smad4-null pancreatic cancer cell line, Capan-1 (Figures 3b and 4b) . Therefore, we confirmed the induction of p21/WAF1 by TGF-b in Smad4-null cells.
Next, we examined whether the induction of p21/ WAF1 in Smad4-null cells was mediated through the mitogen-activated protein kinase (MAPK) cascade or the TbRI-Smad2/3 pathway. Quantitative RT-PCR of p21/WAF1 mRNA in the presence of PD98059, a MEK inhibitor, or SB-431542, a TbRI inhibitor, was performed. At concentrations up to 50 mM, PD98059 did not affect the inducibility of p21/WAF1, whereas SB-431542 inhibited p21/WAF1 upregulation, indicating that the induction of p21/WAF1 was significantly associated with TbRI-Smad2/3 signaling, but not with the MAPK cascade ( Figure 5 ).
TGF-b-mediated Smad 2/3 translocation into the nuclei of Smad4-null cells
We examined TGF-b-Smad signal transduction into the nuclei of Smad4-null BxPC-3 and HaCaT cells by staining endogenous Smad2/3 using fluorescent immunocytochemistry. Cycloheximide was added to the medium to exclude the influence of de novo protein synthesis in the nucleus. Nuclear translocation of Smad2/3 due to TGF-b was observed in BxPC-3 cells, as well as in HaCaT cells in which the TGF-b-Smad pathway is intact (Figures 6a-d) . Moreover, the TbRI inhibitor SB-431542 eliminated the translocation in BxPC-3 cells (Figures 6e and f) .
It was therefore concluded that the TGF-b-Smad signal could be transduced independently of Smad4 to activate p21/WAF1 expression.
Smad 2/3-dependent transcriptional activation of the p21/ WAF1 promoter in Smad4-null cells
To investigate whether the TGF-b-Smad2/3 signal would activate the transcription of the p21/WAF1 promoter in Smad4-null cells, luciferase assays were performed using reporter constructs that contained the p21/WAF1 promoter sequence. TGF-b stimuli driven by a constitutively active TbRI showed transcriptional activation of the 2.4-kb p21/WAF1 promoter construct p21P 0 , and the activation was significantly increased by cotransfection of Smad2 or 3 ( Figure 7 ). This promoter sequence is known to contain the p21/ WAF1-inducing p53-binding sequence (Datto et al., 1995) and five Sp1-binding sites (Moustakas and Kardassis, 1998) through which the Smad complex of Smad2/3/4 binds and activates transcription (Moustakas and Kardassis, 1998; Pardali et al., 2000) . Therefore, we used the reporter assay to examine the deletion constructs p21P 0 Dp53, in which the p53-binding sequence was deleted (Dp53), and p21P 0 SmaD2, in which the clustered Sp1-binding sites were deleted (DSp1). The Dp53 construct showed transcriptional activation similar to that of wild-type p21P 0 , whereas marked loss of activation was observed with the DSp1 construct. These results indicate that the TGF-b signal activates transcription of the p21/WAF1 promoter, in cooperation with Smad2/3, through the Sp1 sites in Smad4-null cells ( Figure 7 ). Finally, we used a bromodeoxyuridine (BrdU) incorporation assay to analyse the ability of TGF-b to inhibit the growth of Smad4-null cells. TGF-b signaling produced up to 80% growth inhibition of BxPC-3 cells (control), and the effect was down to 27% by the TbRI inhibitor SB-431542 (Figure 8 ).
Taken together, these results demonstrate that, even in Smad4-null cells, TGF-b signaling could upregulate p21/WAF1 through Smad2/3 to inhibit cell growth.
Discussion
Smad signaling, which is the only well-characterized pathway downstream of TGF-b, is believed to respond to most of the signals from TGF-b. Although the existence of a non-Smad pathway has been demonstrated (Hartsough and Mulder, 1995; Engel et al., 1999; Hocevar et al., 1999; Bhowmick et al., 2001; Yu et al., 2002) , it has not been elucidated to the same extent as the Smad pathway. In the present study, the microarray data suggest that the TGF-b signal engages only a small fraction of the 2280 arrayed genes and that the Smad4- . After 24 h, the cells were incubated with or without 2.5 ng/ml TGF-b1 for an additional 24 h, and the dual luciferase assay was performed. The firefly luciferase activity of p3TP-lux was normalized to the Renilla luciferase activity of pRL-SV40. The level of luciferase in cells that contained the empty vector and in the absence of TGF-b was assigned a value of 1.0, and the relative activities are shown. TGF-b-Smad signaling was restored by the reintroduction of Smad4. (b) The BxPC-3 cells were transfected with 0.39 mg of either E2F-luc or pGL3-Basic-TATA (control plasmid) in place of p3TP-lux and were then subjected to the process described in (a). The ratios of the levels of E2F-luc to pGL3-Basic-TATA were analysed. E2F activity was significantly suppressed in Smad4-expressing cells. The activity of the cells that contained the empty vector and in the absence of TGF-b was set at 100%, and the relative activities are shown. The mean and standard error (s.e.) values were obtained from three independent experiments that were performed in duplicate or triplicate. Bar, s.e.; *Po0.01 Total cell lysates of Capan-1 cells that were incubated with or without 10 ng/ml of TGF-b1 for 0-2 h were analysed as described in (a) Figure 5 The p21/WAF1 mRNA upregulation by TGF-b is mediated through TbRI-Smad2/3 signaling in Smad4-null cells. BxPC-3 cells were treated with 20 mM PD98059, 1 mM SB-431542, or DMSO (control) for 1 h and were then incubated with or without 10 ng/ml TGF-b1 for 2 h. Total RNA was extracted from these cells, and aliquots of 5 mg of RNA were used for reverse transcription and quantitative RT-PCR analysis using the realtime PCR system. Total RNA from BxPC-3 cells, which were simultaneously incubated for 0 h without pretreatment, was used as a baseline. Quantification of the ratio of p21/WAF1 to GAPDH mRNA showed statistically significant upregulation by TGF-b with DMSO and PD98059, but the upregulation was inhibited with SB-431542. The mean and s.e. values were obtained from three independent experiments. Bar, s.e.; *Po0.02 Smad 2/3-dependent transcriptional activation on the p21/WAF1 promoter in Smad4-null cells. BxPC-3 cells were cotransfected with a p21/WAF1 promoter construct (p21P 0 , p21P 0 Dp53, or p21P 0 SmaD2), pRL-SV40, Smad2 or Smad3 expression plasmid, or the empty vector. TGF-b stimulation was driven by cotransfection with a constitutively active TbRI expression plasmid, TbRI(T204D). After 48 h, the cells were lysed and analysed with the dual luciferase assay. The firefly luciferase activity of the p21/WAF1 promoter construct was normalized to the Renilla luciferase activity of pRL-SV40. The level of luciferase in cells that contained the empty vector and in the absence of TGFb was assigned a value of 1.0, and the relative activities are shown.
The p21P
0 and Dp53 constructs demonstrated Smad2/3-dependent transcriptional activation by TGF-b, whereas the DSp1 construct showed markedly reduced activity. These results indicate that Smad2/3 is involved in p21/WAF1 induction through the Sp1 sites in Smad4-null cells, as in Smad2/3/4-intact cells. Three independent experiments were performed in triplicate. Bar, s.e.; *Po0.01; **Po0.05 Smad4-independent gene regulation by TGF-b H Ijichi et al 2001). However, there were no overlaps with the present study. This may be due to differences in the cell lines, in the organs used to derive the cell lines, or in the microarrays used.
In this study, we showed that p21/WAF1 is upregulated by TGF-b via a Smad4-independent pathway in Smad4-null pancreatic cancer cells. This is an interesting outcome because p21/WAF1 is considered a Smad4-dependent target of TGF-b (Grau et al., 1997; Moustakas and Kardassis, 1998; Pardali et al., 2000) . We also showed that the Smad2/3 signal could be transduced in the absence of Smad4, consequently inducing p21/ WAF1. As no common Smad mediator (Co-Smad) other than Smad4 has been reported in mammalian cells, we propose that a novel, alternative Co-Smad, which can transport Smad2/3 to the nucleus and regulate the Smad4-independent target genes including p21/WAF1, may be involved in this signaling pathway. In Smad2/3/4-intact HaCaT cells, the Ras/Raf/MAPK pathway has been reported to act as a Smad2/3/4-independent signal to mediate p21/WAF1 induction by TGF-b (Hu et al., 1999) . The MAPK cascade seems not to be involved in p21/WAF1 induction, but a Smad2/3-dependent signal downstream of TbRI is required in Smad4-null BxPC-3 cells. The clustered Sp1-binding sites on the p21/WAF1 promoter region are known to be responsible for Smad2/3/4-dependent p21/WAF1 upregulation (Moustakas and Kardassis, 1998; Pardali et al., 2000) . The present study indicated that Smad2/3 and Sp1 are also important in Smad4-independent p21/ WAF1 upregulation.
The upregulation of p21/WAF1 is considered one of the mechanisms behind TGF-b-induced cell growth inhibition. Whereas most cancer cell lines are resistant to the growth inhibition mediated by impaired TGF-bSmad signaling (Grau et al., 1997; Villanueva et al., 1998; Grady et al., 1999) , the Smad4-null BxPC-3 cells showed TGF-b-induced growth inhibition in the BrdU incorporation assay, consistent with previous studies (Dai et al., 1999; Giehl et al., 2000; Simeone et al., 2000) . The transcriptional activity of E2F-luc was also suppressed by up to 50% by TGF-b, even without the restoration of Smad4 activity (Figure 2b ). Although an association was drawn between the MAPK pathway and growth inhibition in previous reports, this correlation remains controversial (Dai et al., 1999; Giehl et al., 2000) . In this study, the observation that a TbRI inhibitor diminished the growth inhibition effect of TGF-b suggests that Smad2/3-dependent signaling may inhibit growth through p21/WAF1 upregulation in Smad4-null cells. As the cDNA chip used in this study did not include other CDK inhibitor genes, such as p15/ INK4b or p27/KIP1, the contribution of these genes to Smad4-independent growth inhibition by TGF-b remains to be examined.
Recently, new findings have emerged regarding the Smad-independent pathways. In these pathways, p38 and c-Jun amino-terminal kinase, which are stressactivated MAPKs, and Rho, which is a small GTPase, were reported to be involved in the induction of apoptosis, EMT, cell motility, and cancer cell invasion (Bhowmick et al., 2001; Yu et al., 2002) . In the present study, we demonstrated the existence of a Smad4-independent pathway, but the genes associated with EMT or cell invasion could not be identified with the microarrays. This may be because the number of genes screened in this study was limited. Additional components of the Smad4-independent pathway may be found among other subsets of genes, and the gene expression profiles may differ depending on the cell type.
In conclusion, we demonstrated Smad4-independent p21/WAF1 induction by TGF-b through Smad2/3 signaling, which may contribute to cell growth inhibition, in Smad4-null pancreatic cancer cells. Our results suggest that the Smad4-independent pathway may be as widespread as the Smad4-dependent pathway downstream of TGF-b. A comprehensive understanding of the intracellular dynamics of pancreatic cancer is expected to lead to the development of novel therapeutic targets.
Materials and methods

Cell lines
The pancreatic cancer cell lines BxPC-3, with homozygous deletion of the Smad4 gene , and Capan-1, in which neither the Smad4 mRNA nor protein are expressed , were purchased from the American Type Culture Collection (Rockville, MD, USA). The BxPC-3 Capan-1 cells were maintained in the recommended culture medium RPMI1640 (Sigma, St Louis, MO, USA) and Iscove's modified Dulbecco's medium (Sigma), respectively. The spontaneously transformed keratinocyte cell line HaCaT (Boukamp et al., 1988) , in which the TGF-b-Smad signaling pathway is intact, was generously provided by NE Fusenig (DKFZ, Heidelberg, Germany) and was maintained in Dulbecco's modified Eagle's medium containing a high concentration of glucose (Sigma). All of the media were supplemented with 10% fetal bovine serum (FBS; Sigma), and the cells were incubated at 371C in a 5% CO 2 atmosphere. 
Plasmids
The pCMV5-Smad4-Flag plasmid, which was described previously (Ijichi et al., 2001) , was used to express the Smad4 protein. The Smad2 and Smad3 protein expression plasmids, pcDEF3-Flag(N)-Smad2 and -Smad3, were also described previously (Kawabata et al., 1998 ). An expression plasmid containing a constitutively active form of TbRI protein, pCMV5-TbRI/HA(T204D) (Eppert et al., 1996) , was provided by J Wrana (Samuel Lunenfeld Research Institute, Toronto, Canada) and was used to drive the TGF-b stimuli. Several firefly luciferase reporter plasmids were used in the luciferase assay. p3TP-lux (Wrana et al., 1992 ) (a gift from J Massague, Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, NY, USA), which contains a major part of the promoter region of the TGF-b-inducible plasminogen activator inhibitor-I gene, was used as the reporter plasmid for the functional analysis of TGF-b-Smad signal transduction. E2F-luc (Lukas et al., 1997) , which contains six tandem repeats of the E2F consensus binding sequence upstream of the TATA box and the firefly luciferase coding sequence, and pGL3-Basic-TATA (Lukas et al., 1997) , which lacks the E2F consensus binding sequence of E2F-luc, were provided by R Booher (Onyx Pharmaceuticals, Richmond, CA, USA) for analysis of E2F transcriptional activity. The p21/WAF1 promoter constructs p21P, p21PDp53, and p21PSmaD2 (Datto et al., 1995) were gifts from X-F Wang (Duke University Medical Center, Durham, NC, USA); the p21/WAF1 promoter sequences were subcloned into pGL3-basic (Promega, Madison, WI, USA) and named p21P 0 , p21P 0 Dp53, and p21P 0 SmaD2, respectively. p21P 0 contains a major (2.4-kb) portion of the p21/WAF1 promoter sequence. The p53-binding site was deleted in p21P 0 Dp53, and the clustered Sp1 sites were deleted in p21P 0 SmaD2. The pRL-SV40 vector (Promega), which contains the SV40 promoter upstream of the coding sequence of Renilla luciferase, was used as the internal control in the luciferase assay.
Reagents PD98059, a MEK inhibitor, was purchased from Daiichi Pure Chemicals (Tokyo, Japan). SB-431542, a specific TbRI inhibitor, was synthesized as described Inman et al., 2002) . A solution of PD98059 or SB-431542 in dimethyl sulfoxide (DMSO, Nacalai tesque, Kyoto, Japan) was prepared. The solution was used after diluting with medium for each assay. DMSO was also used as a blank control.
Transfection and luciferase assays
For the analysis of the effects of Smad4 reintroduction on TGF-b-Smad signaling, the BxPC-3 cells were seeded into sixwell plates, transfected with the plasmids, and analysed with the luciferase assay as described previously (Ijichi et al., 2001) . Briefly, 24 h after seeding, the cells were transfected with p3TP-lux, pRL-SV40, and pCMV5-Smad4-Flag or the empty vector using the transfection reagent Effectene (Qiagen, Hilden, Germany). After 24 h, the cells were incubated with or without 2.5 ng/ml of human recombinant TGF-b1 (R&D Systems, Minneapolis, MN, USA) for an additional 24 h, and the dual luciferase test was performed using the Dual-Luciferase Reporter Assay System (Toyo Inc., Tokyo, Japan). The firefly luciferase activity of p3TP-lux was normalized to the Renilla luciferase activity of pRL-SV40.
For analysis of the transcriptional activity of E2F, either E2F-luc or pGL3-Basic-TATA was cotransfected instead of p3TP-lux. The cells were subsequently treated as described above. The ratio of the activity of E2F-luc to that of pGL3-Basic-TATA was analysed.
For the analysis of the transcriptional inducibility of p21/ WAF1 by TGF-b, BxPC-3 cells were cotransfected with the p21/WAF1 promoter construct (p21P 0 , p21P 0 Dp53, or p21P 0 SmaD2), pRL-SV40, and Smad2 or Smad3 expression plasmid, or the empty vector, along with a constitutively active TbRI expression plasmid or the empty vector. After 48 h, the cells were lysed and subsequently treated as described above. Three independent experiments were performed in triplicate for each reporter assay.
mRNA preparation for cDNA microarray analysis BxPC-3 cells were seeded into culture dishes 10 cm in diameter and transfected after 24 h with 1 mg of pCMV5-Smad4-Flag or the empty vector using Effectene. After a further 24 h, the cells were incubated with or without 10 ng/ml of human recombinant TGF-b1 for 2 h. Total cellular RNA was extracted using the acid guanidinium isothiocyanate/phenol-chloroform method, according to the manufacturer's instructions (ISOGEN; Nippon Gene, Tokyo, Japan). Poly(A) mRNA was prepared from the total RNA using an Oligotex-dT30 mRNA Purification Kit (TaKaRa Shuzo, Tokyo, Japan). Four different samples were obtained: (a) cells that were transfected with the empty vector and incubated without TGF-b1; (b) cells that were transfected with the empty vector and treated with TGFb1; (c) cells that were transfected with the Smad4 expression plasmid and incubated without TGF-b1; and (d) cells that were transfected with the Smad4 expression plasmid and treated with TGF-b1 (Figure 1a) .
cDNA microarray analysis
The cDNA microarray, which consisted of 2304 distinct cDNA clones, was generated as described previously (Otsuka et al., 2001) . Briefly, the PCR-amplified cDNA products were mixed with nitrocellulose in DMSO and immediately spotted onto carbodiimide-coated glass slides using a robotic system (SPBIO-2000; Hitachi Software Engineering Co., Yokohama, Japan). The human cDNA clones were purchased from Research Genetics (Huntsville, AL, USA). In this study, we spotted 2280 sequence-validated cDNAs onto the array. This array included the cDNAs of housekeeping genes such as the human b-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes, which served as internal controls, and the luciferase genes of Photinus pyralis, which acted as negative controls.
Fluorescent cDNA probes (Cy5-or Cy3-labeled) were prepared from 2 mg of each of the mRNA samples (a)-(d). The labeled probe pairs of (a) and (b), (b) and (d), or (a) and (d) were applied onto the microarray followed by incubation at 651C overnight under humid conditions. Fluorescent images of the hybridized microarrays were scanned with a fluorescence laser confocal slide scanner (Scan Array 4000; GSI Lumonics, Tokyo, Japan) and analysed with Quant Array (GSI Lumonics), according to the manufacturer's instructions. The analyses with probes (b) and (a) were compared to detect clones that were putatively regulated by TGF-b in a Smad4-independent manner (Group 1). Comparison of the analyses with probes (d) and (b) identified clones that were putatively regulated by TGF-b in a Smad4-dependent manner (Group 2), and comparative analyses with probes (d) with (a) detected clones that were putatively induced by TGF-b in both Smad4-dependent and -independent fashions (Group 3) (Figure 1b) .
RT-PCR analysis of p21/WAF1 mRNA expression
BxPC-3 and Capan-1 cells were seeded as described above and incubated with or without 10 ng/ml of human recombinant TGF-b1 for 0-2 h. Total RNA was extracted from each sample, and RT-PCR analysis was performed to verify the microarray data. The cDNA templates for RT-PCR were synthesized from 5 mg of total RNA using SuperScript II reverse transcriptase and the oligo(dT) primer (Sawady, Tokyo, Japan). PCR amplification and quantification were performed using the Light Cycler real-time PCR System (Roche Diagnostics, Tokyo, Japan). The primers for the p21/ WAF1 gene were: 5 0 -CAGGGGACAGCAGAGGAAGA-3 0 and 5 0 -TTAGGGCTTCCTCTTGGAGAA-3 0 . As a control, the GAPDH gene was amplified by PCR using the following primers: 5 0 -ACCACAGTCCATGCCATCAC-3 0 and 5 0 -TCCACCACCCTGTTGCTGTA-3 0 . The PCR mixtures, which contained 2 ml of a 10-fold dilution of the RT product, 0.5 mM of each primer, and 3 mM MgCl 2 , were incubated for 2 min at 951C and then subjected to 40 cycles of 951C for 0 s, 551C for 10 s, and 721C for 10 s. The PCR products were electrophoresed on 1.5% agarose/ethidium bromide gels to confirm the expected product sizes. The ratios of the amounts of p21/WAF1 to GAPDH mRNA in each sample were analysed. To examine the involvement of the MAPK cascade or the TbRI-Smad2/3 pathway in p21/WAF1 mRNA induction by TGF-b, 10-50 mM PD98059 or 1-3 mM SB-431542 were added to BxPC-3 cells 1 h before TGF-b stimulation, respectively, followed by RT-PCR analysis as described above. DMSO was added to the cells as a control. RNA samples were extracted on three separate occasions and used for RT-PCR analysis.
Western blotting of the p21/WAF1 protein Total cell lysates of BxPC-3 and Capan-1 cells that were incubated with or without 10 ng/ml TGF-b1 for selected periods were quantified, and equivalent amounts of protein were resolved on SDS-polyacrylamide gels (PAGE). Western blotting of the p21/WAF1 protein was performed as described previously (Otsuka et al., 2000) , except that different antibodies were used. The anti-p21/WAF1 mouse monoclonal antibody (BD Transduction Laboratories, Lexington, KY, USA) was diluted 1 : 500 and used as the primary antibody, while horseradish peroxidase-conjugated anti-mouse immunoglobulin (Amersham Pharmacia Biotech, Buckinghamshire, UK) was used at a dilution of 1 : 1000 as the secondary antibody. The intensity of the blots was quantified using LAS-2000 computed detection system (Fuji film, Tokyo, Japan).
Indirect immunofluorescence microscopy
Fluorescent immunocytochemistry was performed to detect endogenous Smad2 and Smad3 in BxPC-3 and HaCaT cells. The cells (1 Â 10 5 /well) were seeded in culture medium with 10% FBS in eight-well chamber slides (Nalge Nunc, Naperville, IL, USA). The following day, the cells were pretreated for 30 min with 20 mg/ml cycloheximide (Sigma), which is an inhibitor of protein synthesis, and were incubated with or without 2 ng/ml TGF-b1 for 60 min. The cells were then fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) and permeabilized with 0.1% Triton X-100 in PBS. The slides were blocked with 2% normal rabbit serum in PBS. The primary antibody was anti-human Smad2/3 mouse monoclonal antibody (BD Transduction Laboratories), and the secondary antibody was fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse immunoglobulin (DAKO, Carpinteria, CA, USA). The primary and secondary antibodies were used at dilutions of 1 : 100 in a 10-fold dilution of the blocking buffer. The interval washes were carried out with PBS. Nuclear staining was achieved with 2 mg/ml propidium iodide, and the samples were mounted in fluorescence mounting medium (DAKO). The fluorescence of the samples was observed immediately using a confocal microscope system (TCS SL; Leica, Heidelberg, Germany). To assess the effects of the TbRI inhibitor, 1 mM SB-431542 or DMSO (control) was added to the cells 1 h before TGF-b stimulation, followed by immunofluorescent analysis as described above.
BrdU incorporation assay
BxPC-3 cells (1 Â 10 4 cells) were seeded in 96-well plates and stimulated 24 h later with 0, 0.1, 1, and 10 ng/ml TGF-b1. After a 24-h incubation, the cells were fixed and assayed by cell proliferation ELISA using a BrdU colorimetric kit (Roche Diagnostics) according to the manufacturer's instructions. For the last 4 h of incubation, BrdU solution was added to the wells to label the proliferating cells. The effects of the TbRI inhibitor were also examined in his assay by adding SB-431542 1 h before TGF-b stimulation.
